METHODS: This study enrolled 28 adult patients (>18 years) that received the tablet (iPad)-based ASTHMA-Educator on-site at the Montefiore Allergy/Immunology clinic at baseline, 2 months, and 4 months. We measured Asthma Control Test (ACT), Asthma Knowledge Questionnaire (AKQ), and Mini-Asthma Quality of Life Questionnaire (mini-AQLQ) scores at these time-points; at each of these time-points, we also evaluated asthma emergency department visits, asthma hospitalizations, and prednisone use in the past 2 months. We compared the baseline versus 2 months, and baseline versus 4-months values through the 2-sample paired t-test.
RESULTS: Compared to baseline, mean scores for the ACT (15.4 vs. 17.1, p=0.05), AKQ (11.8 vs. 12.3, p=0.09), and mini-AQLQ (56.7 vs. 60.6, p=0.17) increased for patients at 2 months follow-up. Compared to baseline, patients at 4 months follow-up demonstrated statistically significant increased ACT scores (15.4 vs. 17.7, p= 0.02). Also compared to baseline, mean asthma-related emergency department visits (0.57 vs. 0.25, p=0.16), hospitalizations (0.21 vs. 0.04, p=0.10), and prednisone use (0.96 vs. 0.68, p=0.23) in the last 2 months decreased for patients at 4 months follow-up.
CONCLUSIONS: Through use of the ASTHMA-Educator, patients showed improved asthma control, asthma knowledge, and asthma quality of life. Patients also demonstrated post-intervention decreases in asthma-related emergency department visits, hospitalizations, and prednisone use.